Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06770764RecruitingPhase 1
Testing ODC-IL2 for advanced solid tumors
This trial tests a new drug called ODC-IL2 for people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help your immune system fight cancer. The study starts with small doses to find the best dose, then expands to see how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06840886RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
Scottsdale, ArizonaAges 18 years+ - NCT07713550Recruiting
Genetic profiling to guide treatment for advanced solid tumors
This study tests whether analyzing the DNA of your tumor (from a tissue sample or blood draw) can help find the best treatment for your advanced cancer. Researchers will look for genetic changes that could make you eligible for targeted therapy or a clinical trial.
AnderlechtAges 18 years+ - NCT06004245RecruitingPhase 1
Study of VVD-133214 for advanced solid tumors
This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Wuhan, HubeiAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT06598800RecruitingPhase 1
Study of BG-T187 alone or with other drugs for advanced solid tumors
This trial tests a new treatment, BG-T187, given alone or with other medicines for people with advanced solid tumors that have spread or cannot be removed. It is for those who have already tried other treatments.
Hackensack, New JerseyAges 18 years+ - NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT07414836RecruitingPhase 1
First test of new drug BG-C0979 for advanced solid tumors
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
St Louis, MissouriAges 18 years+ - NCT06859762RecruitingPhase 1
YL217 for advanced solid tumors (first-in-human)
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
Phoenix, ArizonaAges 18 years+ - NCT06736704RecruitingPhase 1/Phase 2
Study of SNV4818 for advanced solid tumors with PIK3CA mutation
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06632574RecruitingPhase 1
Paclitaxel liposomes via artery for advanced solid tumors
This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.
NanjingAges 18 years+ - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Los Angeles, CaliforniaAges 18 years+ - NCT06439589RecruitingPhase 1/Phase 2
Drug combo for advanced solid tumors
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Zhengzhou, HenanAges 18–75 - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Huntersville, North CarolinaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,344 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.